GlassScriptPhysician profile
Usman C Ramzan
NPI 1356387823
$2,316.55
in general payments reported to CMS, 2019-2025
32 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.85 · 2020: $299 · 2021: $478 · 2022: $475 · 2023: $649 · 2024: $100 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $278.88 | 2021-2023 | |
| Glaxosmithkline, LLC. | $274.85 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $254.94 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pulmonx Corporation | $245.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $188.79 | 2020-2025 | Breztri |
| Astellas Pharma US INC | $115.05 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $108.55 | 2020-2021 | |
| Amarin Pharma, INC. | $102.75 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $98.58 | 2020-2021 | |
| Lilly USA, LLC | $73.95 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $56.34 | 2023 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $48.59 | 2023 | Xtampza |
| Abbott Laboratories | $40.09 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $38.92 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $38.66 | 2022-2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $31.93 | 2019-2020 | |
| Indivior INC. | $30.39 | 2019 | |
| Axsome Therapeutics, INC. | $28.48 | 2023 | Sunosi |
| Avanir Pharmaceuticals, INC. | $27.79 | 2022 | |
| Gilead Sciences, INC. | $23.67 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.94 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.48 | 2020 | |
| Pfizer INC. | $19.96 | 2024 | |
| Phadia US INC. | $17.12 | 2024 | Immunocap |
| Endo Pharmaceuticals INC. | $15.51 | 2021 | |
| Amgen INC. | $15.31 | 2023 | Prolia, Evenity |
| Kowa Pharmaceuticals America, INC. | $15.30 | 2022 | |
| Eisai INC. | $15.20 | 2020 | |
| Alkermes, INC. | $12.85 | 2019 | |
| Lundbeck LLC | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Ramzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.